Ro07-5220

Ro07-5220

Ro07-5220 is a sedative and anxiolytic drug in the benzodiazepine family. It was first synthesized in the 1970s by Roche Pharmaceuticals and has been studied for its potential use in the treatment of anxiety disorders and insomnia.

Chemistry

Ro07-5220 is a benzodiazepine, a class of drugs that are derivatives of 1,4-benzodiazepine. Like other benzodiazepines, Ro07-5220 has a central benzene ring fused to a seven-membered diazepine ring. The molecular structure of Ro07-5220 is similar to that of other benzodiazepines, with the exception of a fluorine atom at the 7th position of the diazepine ring, which is unique to this compound.

Pharmacology

Ro07-5220 acts as a GABA_A receptor agonist, like other benzodiazepines. It enhances the effect of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABA_A receptor, resulting in sedative, sleep-inducing, anxiolytic, anticonvulsant, and muscle relaxant properties.

Clinical Use

While Ro07-5220 has been studied for its potential use in the treatment of anxiety disorders and insomnia, it is not currently marketed for medical use. The drug has been shown in animal studies to have a lower risk of dependence and withdrawal symptoms compared to other benzodiazepines, but further research is needed to confirm these findings in humans.

See Also

• Benzodiazepine
• GABA_A receptor
• Roche Pharmaceuticals

‎